{
  "title": "Orforglipron vs oral semaglutide",
  "page": "https://stemcellatlas.com/en/compare/orforglipron-vs-oral-semaglutide",
  "snapshot_date": "2026-08-30",
  "headers": [
    "Outcome at 52 weeks",
    "Orforglipron 36 mg",
    "Oral semaglutide 14 mg"
  ],
  "rows": [
    [
      "Study / population",
      "ACHIEVE-3: adults with type 2 diabetes on metformin",
      "Same trial population"
    ],
    [
      "Randomised participants",
      "423",
      "425"
    ],
    [
      "HbA1c change, percentage points",
      "−1.91",
      "−1.47"
    ],
    [
      "Gastrointestinal events",
      "58%",
      "45%"
    ],
    [
      "Stopped treatment because of adverse events",
      "10%",
      "5%"
    ]
  ],
  "scope": "ACHIEVE-3 higher-dose study arms only, not Foundayo versus Wegovy for obesity. HbA1c: treatment-regimen analysis; adverse events: observed study rates. Doses identify study arms, not prescribing or switching instructions.",
  "sources": [
    "https://pubmed.ncbi.nlm.nih.gov/41765029/",
    "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s002lbl.pdf",
    "https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program"
  ],
  "registry_records": [],
  "rights": "Underlying source rights remain with their respective owners. No licence for the underlying papers or registry is granted by this export."
}